2020
Prospective, randomized, double-blind, placebo-controlled evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia
Paidas MJ, Tita ATN, Macones GA, Saade GA, Ehrenkranz RA, Triche EW, Streisand JB, Lam GK, Magann EF, Lewis DF, Dombrowski MP, Werner EF, Branch DW, Habli MA, Grotegut CA, Silver RM, Longo SA, Amon E, Cleary K, How HY, Novotny SR, Grobman WA, Whiteman VE, Wing DA, Scifres CM, Sibai BM. Prospective, randomized, double-blind, placebo-controlled evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia. American Journal Of Obstetrics And Gynecology 2020, 223: 739.e1-739.e13. PMID: 32780999, DOI: 10.1016/j.ajog.2020.08.004.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravenousAdolescentAdultAntithrombin ProteinsCesarean SectionDelivery, ObstetricDouble-Blind MethodFemaleFetal DistressGestational AgeHumansInfant, Premature, DiseasesInfant, Small for Gestational AgeMiddle AgedNeonatal SepsisPerinatal MortalityPre-EclampsiaPregnancyPregnancy Trimester, SecondPregnancy Trimester, ThirdProspective StudiesRecombinant ProteinsYoung AdultConceptsRecombinant human antithrombinPreterm preeclampsiaExpectant managementMorbidity scoreHuman antithrombinPlacebo-controlled clinical trialPlacebo-controlled evaluationPlacebo-controlled trialMedian gestational ageMaternal complicationsVersus PlaceboFetal outcomesMaternal outcomesPreterm deliveryEndothelial dysfunctionSecondary outcomesSingleton pregnanciesStandard therapyLoading dosePrimary outcomeWeeks' gestationGestational ageContinuous infusionClinical trialsSaline infusion
2015
Recombinant Human Antithrombin in Pregnant Patients with Hereditary Antithrombin Deficiency: Integrated Analysis of Clinical Data
Paidas MJ, Triche EW, James AH, DeSancho M, Robinson C, Lazarchick J, Ornaghi S, Frieling J. Recombinant Human Antithrombin in Pregnant Patients with Hereditary Antithrombin Deficiency: Integrated Analysis of Clinical Data. American Journal Of Perinatology 2015, 33: 343-349. PMID: 26461927, DOI: 10.1055/s-0035-1564423.Peer-Reviewed Original ResearchConceptsRecombinant human antithrombinVenous thromboembolismPregnant patientsDoses of anticoagulationHigh VTE riskPostpartum venous thromboembolismHereditary antithrombin deficiencyHuman antithrombinOnset of laborAnticoagulation therapyVTE eventsVTE riskCesarean deliveryTherapy durationProphylactic dosesWeight heparinPeripartum periodClinical trialsClinical dataAntithrombin deficiencyPatientsBody weightIU/TherapyDoses
2013
347: Recombinant human antithrombin (rhAT) for prevention of venous thromboembolism (VTE) in pregnant patients with hereditary antithrombin deficiency (HD)
Paidas M, Triche E, James A, Ballard T, Lowry S. 347: Recombinant human antithrombin (rhAT) for prevention of venous thromboembolism (VTE) in pregnant patients with hereditary antithrombin deficiency (HD). American Journal Of Obstetrics And Gynecology 2013, 208: s154. DOI: 10.1016/j.ajog.2012.10.512.Peer-Reviewed Original Research